Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇨🇦CA · Medicine#1815K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1.5K to 9K🎙 Daily cadence·377 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
5K to 30K🇨🇦100% - Active Followers
Loyal subscribers who consistently listen
2K to 12K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection
Jun 25, 2026
Unknown duration
Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions
Jun 24, 2026
Unknown duration
Adagio Files FDA Submission For Ventricular Ablation System
Jun 24, 2026
Unknown duration
Ban Of Red Food Dye 3: Safety Implications For Families
Jun 24, 2026
Unknown duration
Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis
Jun 23, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6/25/26 | Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection | Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors. | — | ||||||
| 6/24/26 | Beyond the Prescription Pad: Breast Cancer Survivorship via Combined Lifestyle Interventions | A structured low-GI Mediterranean diet, daily brisk walking, and vitamin D supplementation significantly reduced recurrence risk in HR-positive breast cancer survivors while improving metabolic health. | — | ||||||
| 6/24/26 | Adagio Files FDA Submission For Ventricular Ablation System | Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes. | — | ||||||
| 6/24/26 | Ban Of Red Food Dye 3: Safety Implications For Families | FDA’s Red No. 3 ban will phase the dye out of foods and medicines by 2027, prompting reformulations while reassuring consumers about minimal health risk. | — | ||||||
| 6/23/26 | Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis | Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options. | — | ||||||
| 6/23/26 | Neurovalens CEO Outlines Noninvasive Neuromodulation Plans | Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges. | — | ||||||
| 6/23/26 | Shifting Care in Acute Leukemia: The Dawn of Menin Inhibition | Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias. | — | ||||||
| 6/22/26 | Clinician Adoption of AI to Detect LV Systolic Dysfunction in Everyday Practice | AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes. | — | ||||||
| 6/22/26 | How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC | A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy. | — | ||||||
| 6/22/26 | Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC | A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/18/26 | The FDA’s New Tzield Approval Fundamentally Alters Stage 3 Pediatric Type 1 Diabetes Management | FDA approval of Tzield marks a breakthrough in Type 1 diabetes care, preserving remaining insulin-producing cells and shifting treatment from replacement to disease modification. | — | ||||||
| 6/18/26 | Re-evaluating N- Acetylcysteine as a Time-Buying Neuroprotectant in Acute Stroke Care | N-acetylcysteine (NAC) shows promise as a neuroprotective adjunct in acute ischemic stroke, potentially preserving brain tissue, enhancing reperfusion outcomes, and improving recovery during treatment delays. | — | ||||||
| 6/17/26 | Metabolomic Signature May Predict Type 2 Diabetes Risk | A novel 44-metabolite signature improves prediction of future type 2 diabetes risk, enabling earlier identification of high-risk individuals and supporting personalized prevention strategies. | — | ||||||
| 6/17/26 | Many Children with Uncontrolled Asthma Lack Access to Specialty Care | Digital health and telemedicine are transforming healthcare delivery through virtual care, remote monitoring, and enhanced patient engagement, improving access, efficiency, outcomes, and care coordination. | — | ||||||
| 6/17/26 | FDA Report on Forever Chemicals: Implications for Cosmetics | FDA scrutiny of PFAS “forever chemicals” in cosmetics may drive stricter regulations, reformulated products, greater labeling transparency, and increased consumer demand for safer beauty options. | — | ||||||
| 6/16/26 | Jupiter Endovascular Reports Positive Vertex Pulmonary Embolectomy Results | The investigational Vertex Pulmonary Embolectomy System demonstrated promising results in intermediate-risk pulmonary embolism, improving right-heart function and pulmonary pressures while supporting safer, catheter-based clot removal. | — | ||||||
| 6/16/26 | Protecting Infants From Measles During Outbreaks: Guidance for Parents and Clinicians | Rapid measles response is critical for infants, who remain highly vulnerable before routine vaccination. Early exposure management, timely immunization, isolation protocols, and coordinated public health action help prevent severe complications, limit transmission, and protect young children during outbreaks. | — | ||||||
| 6/16/26 | Carotid Plaque Imaging Enables Improved Carotid Artery Management | Advanced carotid plaque imaging evaluates plaque biology, helping clinicians identify stroke risk more accurately, personalize treatment decisions, and improve prevention beyond stenosis measurement alone. | — | ||||||
| 6/12/26 | THT 2026: First-In-Human Smart Implant—Heart Failure Decongestion | A novel smart device for heart failure decongestion uses pressure-guided fluid redistribution to reduce congestion, potentially improving symptoms, lowering hospitalizations, and enabling remote monitoring. | — | ||||||
| 6/12/26 | Sphingolipid to Steroid Ratio May Predict Asthma Exacerbations | Metabolomic profiling is emerging as a promising tool for predicting asthma exacerbations, enabling earlier risk identification, personalized treatment strategies, and potentially reducing hospitalizations through proactive disease management. | — | ||||||
| 6/12/26 | Early Promise of Flexible ECAP-Based Spinal Cord Stimulation for Chronic Pain Relief | ECAP-guided spinal cord stimulation enables real-time, adaptive pain management, offering more consistent symptom relief and reducing reliance on opioids for chronic pain patients. | — | ||||||
| 6/12/26 | Unlocking the Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss and Heart Health | Emerging obesity treatments may deliver both weight-loss and cardiovascular benefits, offering new options to reduce heart disease risk while addressing the growing obesity epidemic. | — | ||||||
| 6/12/26 | Current Status of Retinal Diagnostics In Alzheimer’s Disease | Retinal imaging may offer a noninvasive way to detect early Alzheimer’s-related brain changes, supporting earlier screening, risk assessment, and referral before significant cognitive decline occurs. | — | ||||||
| 6/11/26 | A 24-Year Mortality Analysis of Spinal Muscular Atrophy and a Blueprint for Future Pediatric Care | A 24-year U.S. analysis shows gene-targeted therapies dramatically reduced childhood spinal muscular atrophy mortality, transforming a once-fatal disease into a manageable long-term condition. | — | ||||||
Showing 24 of 525
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.